Anoro Ellipta

DEVICE2 trials

Sponsors

University of Virginia, GlaxoSmithKline

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 2

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Active, not recruitingNCT03002389

University of VirginiaChronic Obstructive Pulmonary Disease

Start: 2017-11-05End: 2028-01-31Target: 95Updated: 2024-11-18

Unknown Phase

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

CompletedNCT03114969

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2017-06-08End: 2018-03-09Updated: 2020-10-28